Moving into the future with advanced therapies
ATMPs represent a great opportunity for the treatment of previously incurable diseases.
In the last decade, many novel medicinal products, also known as Advanced Therapy Medicinal Products (ATMPs), have been further developed and achieved breakthrough success in treating previously untreatable diseases. Numerous gene therapeutics, cell therapeutics, and bioengineered tissue products have already been approved in the EU and the U.S., and the number of ATMPs in clinical trials is increasing continuously on a global scale.
According to the German Medicines Act (AMG) and the European Medicines Agency (EMA), ATMPs represent a heterogeneous group of preparations. These are recombinant nucleic acids, cells, or tissues which are used as gene therapeutics, somatic cell therapeutics, or bioengineered tissue products. They are primarily isolated from blood, bone marrow, or other tissues. They are modified for therapeutic purposes and then administered autologously or allogeneically.